FILANA THERAPEUTICS Business Summary

Filana Therapeutics Inc (FLNA) is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule therapeutics for neurodegenerative diseases, specifically targeting protein misfolding and clearance pathways. The company’s business model is centered on its proprietary "ProteoClear" platform, generating revenue through strategic R&D collaborations, upfront licensing fees, and milestone-contingent payments from global pharmaceutical partners. Its primary business segments are focused on CNS-Targeted Protein Degradation and Precision Neuro-Oncology. Filana competes directly with Denali Therapeutics, Alector, and Arvinas. Within the competitive landscape, Filana distinguishes itself through its industry-leading blood-brain barrier (BBB) permeable degraders, offering a more precise mechanism of action than the broader neuro-immunology approaches of its peers. The leadership team is spearheaded by Co-Founder and CEO Dr. David S. Bredt, a renowned neuroscientist who previously served as the Global Head of Neuroscience at Janssen and Eli Lilly. He is supported by Chief Scientific Officer Dr. John Dunlop, an industry veteran with prior leadership roles at Amgen and Pfizer, and a management team with deep expertise in CNS drug development. Filana is backed by a prestigious syndicate of investors including Atlas Venture, OrbiMed, and Bain Capital Life Sciences. The Board of Directors features prominent industry figures such as Dr. Vicki Sato, former President of Vertex Pharmaceuticals, and Dr. Edward Scolnick, former President of Merck Research Laboratories, providing the company with significant strategic oversight as it advances its late-stage clinical pipeline.